 |
|
Clinical and Humanistic Outcomes in Patients With Gastroesophageal Reflux Disease Converted From Omeprazole to Lansoprazole
Winnie W. Nelson, PharmD;
Lee C. Vermeulen, MS;
Eric A. Geurkink;
David A. Ehlert;
Mark Reichelderfer, MD
Arch Intern Med. 2000;160:2491-2496.
Background Omeprazole and lansoprazole are 2 proton pump inhibitors (PPIs) currently available in the United States. Both PPIs are approved for the treatment of gastroesophageal reflux disease (GERD) and are commonly converted in therapeutic interchange programs.
Objective To measure clinical and humanistic outcomes in patients with GERD converted from treatment with omeprazole to treatment with lansoprazole through a managed care plan policy.
Methods Patients with heartburn or GERD receiving omeprazole covered by a local health plan were surveyed by telephone. Data collected included symptom frequency, severity, over-the-counter heartburn preparation use, diet, lifestyle, and overall satisfaction. Patients were then converted to therapy with lansoprazole and again interviewed after at least 30-day use of the new PPI. Demographic data were obtained from the health plan database for analysis.
Results A total of 105 patients completed both telephone surveys. After the conversion, 37% of the patients experienced more frequent symptoms while awake. Symptom severity score was significantly higher (more severe) after conversion (mean score of 1.34 vs 2.26). Thirty-three percent of study patients consumed more over-the-counter heartburn preparations, and 13% changed their diet more frequently due to heartburn symptoms after conversion. Overall patient satisfaction score decreased significantly (less satisfied) after conversion (mean score of 9.0 vs 7.2). There were no significant differences in alcohol and tobacco consumption before and after conversion, while patients consumed significantly less caffeine after conversion.
Conclusions After the PPI therapeutic interchange from omeprazole to lansoprazole, patients with GERD or heartburn previously stabilized while receiving omeprazole experienced more severe symptoms and expressed decreased patient satisfaction. These results suggest a need to monitor symptoms after similar interchange programs.
From the Center for Drug Policy and Clinical Economics (Dr Nelson and Messrs Vermeulen, Geurkink, and Ehlert), and the Department of Gastroenterology (Dr Reichelderfer), University of Wisconsin Hospital and Clinics, Madison. At the time of the study, Dr Nelson was a research fellow at the University of Wisconsin Hospital and Clinics.
RELATED LETTER
Clinical and Ethical Concerns About Switching Patient Treatment to "Therapeutically Interchangeable" Medications
Jay S. Cohen, Winnie W. Nelson, Lee C. Vermeulen, Eric A. Geurkink, David A. Ehlert, and Mark Reichelderfer
Arch Intern Med. 2001;161(17):2153-2154.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(16):2551-2552.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems
Am J Health Syst Pharm 2008;65:1368-1384.
FULL TEXT
Patient assessment of treatment satisfaction: methods and practical issues
Revicki
Gut 2004;53:iv40-iv44.
ABSTRACT
| FULL TEXT
Adverse Events Due to Discontinuations in Drug Use and Dose Changes in Patients Transferred Between Acute and Long-term Care Facilities
Boockvar et al.
Arch Intern Med 2004;164:545-550.
ABSTRACT
| FULL TEXT
Clinical and Ethical Concerns About Switching Patient Treatment to "Therapeutically Interchangeable" Medications
Cohen et al.
Arch Intern Med 2001;161:2153-2154.
FULL TEXT
Not Easy to Switch Horses, or PPIs, Midstream
JWatch Gastroenterology 2000;2000:5-5.
FULL TEXT
|
